• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Risk of Subsequent Preterm Birth with Prior History: Results from a Population-Based Study

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Tingleff et al. (BJOG, 2021) assessed risk for recurrent preterm birth with a focus on the presence of placental disorders

METHODS:

  • Population-based registry study
    • Norwegian registry
  • Population
    • First and second singleton child born between 1999 and 2014
  • Exposures
    • Preterm first birth
    • Term first birth used as reference
  • Study design
    • Preterm birth definitions
      • Extremely preterm: <28w0d
      • Very preterm: 28w0d to 33w6d  
      • Late preterm: 34w0d to 36w6d
    • Placental disorders
      • Preeclampsia | HELLP | Eclampsia | SGA (birthweight <5%tile)
    • Multivariate logistic regression analyses were performed
    • Adjustments: Placental disorders | Maternal and obstetric history | Socioeconomic factors | Known risk factors for preterm birth
  • Primary outcome
    • Preterm second birth

RESULTS:

  • 213,335 women | 426,670 births
  • Preterm birth (<37 weeks) rates
    • First births: 5.6%
    • Second births: 3.7%
  • Among women with any category of preterm first birth, 17.4% had a preterm second birth
  • Extremely preterm second births occurred most frequently among women with an extremely preterm first birth
    • Extremely preterm second birth incidence: 0.2%
    • Adjusted odds ratio (aOR) 12.90 (95% CI, 7.47 to 22.29)
  • Very preterm second births occurred most frequently after an extremely preterm birth
    • Very preterm second birth incidence: 0.7%
    • aOR 12.98 (95% CI, 9.59 to 17.58)
  • Late preterm second births occurred most frequently after a previous very preterm birth
    • Late preterm second birth incidence: 2.8%
    • aOR 6.86 (95% CI, 6.11 to 7.70)
  • The contribution of placental disorders was most pronounced for recurrent extremely and very preterm birth
    • Placental disorder in both births vs no placental disorder
      • 5.7-fold increase in odds of having an extremely preterm second birth (aOR, 5.72; CI, 4.03-8.12)
      • 6.6-fold increase in the odds of having a very preterm second birth (aOR, 6.63; CI, 5.67–7.75)
      • 3.6-fold increase in odds of late preterm second birth (aOR, 3.58; CI, 3.22–3.98)

CONCLUSION:

  • Approximately 1 in 6 women will experience a preterm second birth
  • Placental disorder contribution was more pronounced for recurrent extremely and very preterm birth than for recurrent late preterm birth
  • The authors state

Placental disorders explained 30~40% of the increased odds for having an extremely or very preterm second birth and explained 10~22% of the increased odds for having a late preterm second birth

Learn More – Primary Sources:

Risk of preterm birth in relation to history of preterm birth: a population-based registry study of 213,335 women in Norway

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Can Obstetric History Predict Preterm Birth Risk in Twins?
Oral Progesterone for the Prevention of Recurrent Preterm Birth?
Does Preterm Delivery Lead to a Lifelong Increased Risk for Hypertension?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site